Navigation Links
MedImmune Announces Winners of the 5th Annual Respiratory, Inflammation and Autoimmunity Research Abstract Competition

GAITHERSBURG, Md., Nov. 17, 2010 /PRNewswire/ -- MedImmune announced the winners of its 5th Annual Research Abstract Competition highlighting the work of the next generation of scientific leaders performing research in areas of respiratory, inflammation and autoimmune (RIA) disease. Graduate students and postdoctoral fellows from around the world were invited to submit abstracts on RIA research as part of a competition sponsored by MedImmune, AstraZeneca's global biologics unit.

First prize of $2,000 was awarded to Jennifer Martinez, Ph.D., Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, for her research topic "The role of LC3- associated phagocytosis in the clearance of dead cells."

Martinez noted: "I am appreciative for the recognition and the opportunity to present my data.  It was also a great chance to learn about research in the field my colleagues are doing around the world."  

Second and third prizes of $1,000 and $500 were awarded respectively to Jeremy Di Domizio, Ph.D., Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, and Donald Simons, Ph.D., of The Wistar Institute, Philadelphia.

"We are impressed by the quality of research that is being conducted by young scientists," said Bahija Jallal, executive vice president of research and development at MedImmune. "This competition, which is one of the many activities MedImmune leads to engage emerging scientists in advancing health and science education, uncovered some extraordinary ideas that could help researchers further understand approaches in the RIA therapeutic area."

The competition was open to graduate students and postdoctoral fellows worldwide, with ten finalists selected to present their research to a panel of MedImmune experts at the company's headquarters in Gaithersburg.  Evaluation of abstracts were based on the following criteria: scientific rationale, description of methodology, suitability of methods to aims, conclusions confirmed by objective results, ethics, scientific value, potential clinical value, originality of work and overall presentation.

About MedImmuneMedImmune, the worldwide biologics unit for AstraZeneca PLC (LSE: AZN.L, NYSE: AZN), has approximately 3,500 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising drug candidates, MedImmune strives to deliver life-changing products, a rewarding career to our employees and a tireless commitment to improving patient health. For more information, visit MedImmune's website at

Notes to Editors:First Place:  Jennifer Martinez, Ph.D., Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN, for her research topic "The role of LC3- associated phagocytosis in the clearance of dead cells."

Second Place:  Jeremy Di Domizio, Ph.D., Department of Immunology, M D Anderson, Houston. The title of his abstract is "A novel class of host-derived etiological agent for autoimmunity: oligomers of endogenous proteins complex with self-nucleic acids and trigger Type I interferon production by plasmacytoid dendritic cells."

Third Place:  Donald Simons, Ph.D., of The Wistar Institute, Philadelphia. The title of his abstract is "Monocytes promote the formation of Th17 cells in inflammatory arthritis."Media Contact:Karen Lancaster(301) 398-5864

SOURCE MedImmune
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MedImmune Focused on Revolutionizing Cancer Care
2. MedImmune to Present Five Abstracts on RSV at Pediatric Academic Societies Annual Meeting
3. MedImmune to Present Data on RSV and Influenza at 2009 American Academy of Pediatrics National Conference & Exhibition
4. MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants
5. MedImmune Presents New Data Demonstrating Increased Risk for Medically Attended RSV in Late-Preterm Infants
6. MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
9. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
10. MedImmune Advances Clinical Development of Antibody Targeting Interleukin-9 in Patients with Asthma
11. MedImmune Initiates First Clinical Trial of Monoclonal Antibody Targeting GM-CSFR in Patients with Rheumatoid Arthritis
Post Your Comments:
(Date:10/13/2015)... 2015  Nanomedical Diagnostics, a biotech company developing ... diagnostics, announces the completion of a Series A ... Ventures. --> ... monitoring and diagnostic platforms that empower individuals to ... will enable the company to commercially release AGILE ...
(Date:10/13/2015)... Oct. 9, 2015 Research and Markets ( ... "Kombucha Market by Types (Bacteria, Yeast, Mold, Others), Flavors ... Flowers, Others), & by Region - Forecasts to 2020" ... --> --> The global ... few years. In terms of value, the market is ...
(Date:10/13/2015)... Oct. 13, 2015   Micell Technologies , Inc. ... and II trials of its MiStent Sirolimus Eluting Absorbable ... ) were presented at the 27th Annual Transcatheter Cardiovascular ... San Francisco , October 11-15. TCT is the ... MiStent SES was designed to optimize vessel healing in ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... October 13, 2015 , ... Purdue University announced Tuesday (Oct. ... Initiative aimed at enhancing Purdue’s life sciences research and graduate education. The initiative ... , The investment will result in cohesive efforts across several colleges and is ...
(Date:10/13/2015)... ... 13, 2015 , ... "My friend's son suffers from eczema, and he had ... an inventor from Platteville, Colo. "I came up with this kit as a way ... to prevent a child from rubbing or scratching his or her face. This protects ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ProText Kinetic ... X . With ProText Kinetic Panel, users can create energetic text animations in any ... preset into the Final Cut Pro X timeline and stylize the text. With intuitive ...
(Date:10/13/2015)... ... October 13, 2015 , ... Relay (, a technology ... today a significant contract that will provide its award-winning private messaging solution to ... the growing success of its Relay program, IBX Wire™, which now has over ...
(Date:10/13/2015)... ... October 13, 2015 , ... Leading Internet marketing product review ... "Publish Academy" training course . Singal's new program, in which he reveals his ... around the Internet are weighing in with reviews. , "Considering the fairly high ...
Breaking Medicine News(10 mins):